breakthrough Archives -

QuintilesIMS’s Cristina Oliva talks to pharmaphorum about her personal highlights from this year’s congress.

ESMO review: advances in immunotherapy, EMA dialogue and patient power

https://pharmaphorum.com/views-and-analysis/esmo-review-advances-immunotherapy-ema-dialogue-patient-power/

The booming interest in new targeted therapies represents a changing of the guard in cancer treatment, from the

Infographic: Solving the challenges of immuno-oncology trials

https://pharmaphorum.com/views-and-analysis/overcoming-challenges-immuno-oncology-trials-60-seconds/

Roche’s PD-L1 drug has generated impressive data in second line lung cancer

Cancer market commentary: Roche’s Tecentriq muscles into NSCLC

https://pharmaphorum.com/esmo-2016/cancer-market-commentary-roches-tecentriq-muscles-nsclc/

Merck unveils impressive data on Keytruda, trumping BMS’ Opdivo

Eye on ESMO: Day Three – Merck & Co. wins big lung cancer battle

https://pharmaphorum.com/esmo-2016/eye-esmo-day-three-merck-co-wins-big-lung-cancer-battle/

Novartis’ phase 3 advanced breast cancer therapy ribociclib shows promise

Eye on ESMO: Day 2 – gamechangers take centre stage

https://pharmaphorum.com/esmo-2016/eye-esmo-day-two-gamechangers-take-centre-stage/

breakthrough